-
公开(公告)号：KR1020090107953A
公开(公告)日：2009-10-14
申请号：KR1020090030580
申请日：2009-04-08
Applicant: 한올바이오파마주식회사
IPC: A61K9/52 , A61K31/41 , A61K31/165 , A61P9/12
CPC classification number: A61K9/2086 , A61K9/28 , A61K9/4808 , A61K31/41 , A61K38/05
Abstract: PURPOSE: A pharmaceutical formulation is provided to obtain medical synergic effect by inducing optimal pharmacological effect and enhance drug complication. CONSTITUTION: A pharmaceutical formulation comprises a compartment containing a pharmacologically active aliskiren and its isomer or its pharmaceutically acceptable salt and a compartment containing a pharmacologically active valsartan and its isomer or its pharmaceutically acceptable salt. One of compartments is an immediate release compartment and the other is an extended release compartment. 40 weight% of active ingredient of the extended release compartment is released until two hour after releasing the ingredient.
Abstract translation: 目的：提供药物制剂，通过诱导最佳药理作用和增强药物并发症获得药效协同作用。 构成：药物制剂包含含有药理学活性的阿利吉仑及其异构体或其药学上可接受的盐的隔室和含有药理学活性缬沙坦及其异构体或其药学上可接受的盐的隔室。 一个隔间是立即释放隔间，另一个是延长释放隔间。 释放40分钟的延长释放隔室的活性成分释放到释放成分2小时之前。
-
公开(公告)号：KR1020090091084A
公开(公告)日：2009-08-26
申请号：KR1020090015058
申请日：2009-02-23
Applicant: 한올바이오파마주식회사
Abstract: A pharmaceutical formulation containing an amlodipine and pitavastatin is provided to treat metabolic diseases and hypertension and prevent complication. A pharmaceutical formulation for treating cardiovascular diseases comprises an immediate-release containing a pitavastatin as a pharmacologically active ingredient or its pharmaceutically acceptable salt and an extended-release containing an amlodipine as a pharmacologically active ingredient or its pharmaceutically acceptable salt. A pharmaceutical formulation for treating cardiovascular disease comprises a pitavastatin The extended-release compartment comprises a water insoluble polymer, hydrophobic compound, hydrophilic polymer or release control material of their mixture. The pharmaceutical formulation comprises the extended-release compartment of a particle, granule, pellet, or tablet and the immediate-release compartment of capsule containing a particle, pellet, or tablet.
Abstract translation: 提供含有氨氯地平和匹伐他汀的药物制剂以治疗代谢疾病和高血压并预防并发症。 用于治疗心血管疾病的药物制剂包括含有匹伐他汀作为药理学活性成分或其药学上可接受的盐的速释药，以及含有氨氯地平作为药理学活性成分或其药学上可接受的盐的延长释放物。 用于治疗心血管疾病的药物制剂包括匹伐他汀。延长释放隔室包含水不溶性聚合物，疏水化合物，亲水性聚合物或其混合物的释放控制材料。 药物制剂包含颗粒，颗粒，丸剂或片剂的缓释隔室和含有颗粒，丸剂或片剂的胶囊的立即释放隔室。
-
公开(公告)号：KR1020090091081A
公开(公告)日：2009-08-26
申请号：KR1020090014956
申请日：2009-02-23
Applicant: 한올바이오파마주식회사
IPC: A61K9/52 , A61K31/40 , A61K31/165 , A61P9/00
CPC classification number: A61K9/209 , A61K9/0004 , A61K31/165 , A61K31/41
Abstract: A pharmaceutical formulation containing aliskiren and atrovastatin in an immediate-release compartment and extended release compartment for preventing and treating syndrome, cardiovascular disease and kidney diseases is provided to improve the drug effect and easily administer by a patient at a different times. A pharmaceutical formulation comprises a compartment containing an aliskiren as a pharmacologically active ingredient, its isomer or its pharmaceutically acceptable salt and a compartment containing an atrovastatin as a pharmacologically active ingredient, its isomer or its pharmaceutically acceptable salt. One of the compartments is an immediate-release compartment and the other is extended-release compartment. The extended-release compartment additionally comprises a water soluble polymer, hydrophobic compound, hydrophilic polymer or release control material of their composite. The pharmaceutical formulation is used for preventing and treating metabolic disease, cardiovascular disease or kidney disease.
Abstract translation: 提供了含有急性释放隔室中的阿利吉仑和阿伐他汀的药物制剂，以及用于预防和治疗综合征，心血管疾病和肾脏疾病的延长释放室，以改善药物效应，并在不同时间容易地由患者施用。 药物制剂包含含有阿利吉仑作为药理活性成分的隔室，其异构体或其药学上可接受的盐和含有阿伐他汀作为药理学活性成分的隔室，其异构体或其药学上可接受的盐。 其中一个隔间是立即释放舱，另一个是延长释放舱。 延长释放隔室另外包含其复合物的水溶性聚合物，疏水化合物，亲水性聚合物或释放控制材料。 药物制剂用于预防和治疗代谢疾病，心血管疾病或肾脏疾病。
-
公开(公告)号：KR1020090037347A
公开(公告)日：2009-04-15
申请号：KR1020080099484
申请日：2008-10-10
Applicant: 한올바이오파마주식회사
IPC: A61K31/405 , A61K31/575 , A61K31/366 , A61P1/16
CPC classification number: A61K45/06 , A61K9/209 , A61K31/404 , A61K31/575 , A61K38/21 , A61K2300/00
Abstract: A pharmaceutical composition for treating hepatitis C virus infection comprising HMG-CoA reductase inhibitor and bile acid is provided to improve inhibitory activity on hepatitis C virus without side effects like anemia by using HMG-CoA reductase inhibitor and bile acid. A pharmaceutical composition for treating hepatitis C virus infection comprises HMG-CoA reductase inhibitor and bile acid. The HMG-CoA reductase inhibitor is at least one selected from the group consisting of fluvastatin, lovastatin, atorvastatin, simvastatin, rivastatin, pitavastatin, rosuvastatin and their salts. The bile acid is at least one selected from the group consisting of ursodeoxycholic acid, cenode oxycholic acid, deoxycholic acid, cholic acid and their salts.
Abstract translation: 提供用于治疗包含HMG-CoA还原酶抑制剂和胆汁酸的丙型肝炎病毒感染的药物组合物，以通过使用HMG-CoA还原酶抑制剂和胆汁酸来改善对丙型肝炎病毒的抑制活性，无副作用，如贫血。 用于治疗丙型肝炎病毒感染的药物组合物包含HMG-CoA还原酶抑制剂和胆汁酸。 HMG-CoA还原酶抑制剂是选自氟伐他汀，洛伐他汀，阿托伐他汀，辛伐他汀，利伐他汀，匹伐他汀，罗苏伐他汀及其盐中的至少一种。 胆汁酸是选自熊去氧胆酸，cenode氧胆酸，脱氧胆酸，胆酸及其盐中的至少一种。
-
公开(公告)号：KR1020090022616A
公开(公告)日：2009-03-04
申请号：KR1020070088139
申请日：2007-08-31
Applicant: 한올바이오파마주식회사
IPC: A61K9/20 , A61K9/16 , A61K9/48 , A61K31/4365
CPC classification number: A61K9/2054 , A61K9/1611 , A61K9/1623 , A61K9/1652 , A61K9/2009 , A61K9/2018 , A61K9/2059 , A61K9/2095
Abstract: An oral administration medicine is provided to prevent a shape problem with tables in a press-forming process and maximize effects of clopidogrel by using a wet granulation method. An oral administration medicine is prepared through a wet granulation method by adding a binding solution containing a low alcohol to clopidogrel besylate. The low alcohol is a C1-C4 alcohol. The 0.01-0.5wt.pt. of low alcohol is added on a 1wt.pt. basis of clopidogrel besylate. The particle size of the clopidogrel besylate is 5-500mum of Sauter mean diameter. The moisture contents of the oral administration medicine is 0.5-3.0%(w/w).
Abstract translation: 提供一种口服给药药物，以防止压制成型过程中的表格形状问题，并通过使用湿法造粒法使氯吡格雷的效果最大化。 口服药物通过湿法造粒法通过将含有低级醇的结合溶液加入到氯吡格雷苯磺酸盐中来制备。 低醇是一种C 1 -C 4醇。 0.01-0.5wt.pt。 的低酒精加入1wt。 氯吡格雷苯磺酸盐的基础。 氯吡格雷苯磺酸盐的粒径为沙特平均直径5-500μm。 口服药物的水分含量为0.5-3.0％（w / w）。
-
Patent Agency Ranking
公开(公告)号：KR1020090005513A
公开(公告)日：2009-01-14
申请号：KR1020070068609
申请日：2007-07-09
Applicant: 한올바이오파마주식회사
IPC: C07C279/26 , C07C279/04 , C07C55/08
Abstract: A metformin malonate is provided to ensure solubility, stability, and adhesion resistance, to treat diabetes and to prevent complications of the patients carrying a metabolic syndrome. A manufacturing method of a metformin malonate having a structure indicated as the chemical formula 1, comprises (i) a step for reacting metformin hydrochloride 2-4 equivalent indicated as the chemical formula 2, sodium hydroxide or potassium hydroxide 2-4 equivalent, and water in an organic solvent to obtain a metformin base indicated as the chemical formula 3, and removing the inorganic salt; and (ii) a step for reacting the product of the step (i) and a malonic acid of the chemical formula 4 in the organic solvent. The reaction solvent is an organic solvent selected from the group consisting of methanol, ethanol, isopropanol, acetone and acetonitrile.
Abstract translation: 提供二甲双胍丙二酸酯以确保溶解性，稳定性和粘合性，以治疗糖尿病并预防携带代谢综合征的患者的并发症。 具有化学式1所示结构的二甲双胍丙二酸酯的制造方法包括（i）使化学式2所示2-4重量级的二甲双胍2-4氢
化钠或氢氧化钾2-4当量的水 在有机溶剂中，得到表示为化学式3的二甲双胍碱，除去无机盐; 和（ii）使步骤（i）的产物与化学式4的丙二酸在有机溶剂中反应的步骤。 反应溶剂是选自甲醇，乙醇，异丙醇，丙酮和乙腈的有机溶剂。-
公开(公告)号：KR100855189B1
公开(公告)日：2008-09-01
申请号：KR1020060065586
申请日：2006-07-12
Applicant: 한올바이오파마주식회사
Abstract: 본 발명은 구강 속붕해성 정제에 관한 것으로서, 더욱 상세하게는 약학적으로 유효한 활성성분으로서 로라타딘 또는 데스로라타딘을 포함하고, 부형제로서 수용성 탄수화물을 사용하며, 붕해제로서 분무 건조된 전분과 분무 건조된 유당을 혼합 사용함으로써, 이로서 제조된 정제가 구강 내에서 빠르게 붕해되어 활성성분의 생체 내 흡수를 촉진할 수 있어 약효의 발현이 빠르며, 복용 시 구강 내의 잔류물이 거의 없어서 잔류감 및 이물감이 적고, 구강 내에서 신속히 붕해되면서도 취급이 용이한 수준 이상의 경도를 가지는 속붕해정을 일반정제기를 사용하여 생산하므로 저비용으로 대량 생산할 수 있는 개선된 구강 속붕해성 정제에 관한 것이다.
구강 속붕해성 정제, 로라타딘, 데스로라타딘, 부형제, 붕해제, 잔류감, 이물감-
78.发明公开
公开(公告)号：KR1020080039303A
公开(公告)日：2008-05-07
申请号：KR1020070109645
申请日：2007-10-30
Applicant: 한올바이오파마주식회사
CPC classification number: A61K31/00 , A61K9/2077 , A61K9/209
Abstract: A controlled release complex composition comprising an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor is provided to be designed to control each of the ingredients releasing at a specific rate by administering the ingredients to have different onset times and be very effective for treating hypertension and preventing complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. A controlled release complex composition comprises a lag time delayed-release portion including an angiotensin-II-receptor blocker as an active ingredient and an immediate release portion including an HMG-CoA reductase inhibitor as an active ingredient, wherein the angiotensin-II-receptor blocker is selected from the group consisting of losartan, valsartan, irbesartan, candesartan, telmisartan, eprosartan, olmesartan and a pharmaceutically acceptable salt thereof, the HMG-CoA reductase inhibitor is at least one selected from the group consisting of simvastatin, lovastatin, atorvastatin, pitavastatin, rosuvastatin, fluvastatin, pravastatin and a pharmaceutically acceptable salt thereof and the lag time delayed-release portion includes a release-controlling material selected from the group consisting of an enteric polymer, a water-insoluble polymer, a hydrophobic compound and a hydrophilic polymer. Further, the 5 to 1200 mg of angiotensin-II-receptor blocker is comprised in the composition.
Abstract translation: 提供了包含血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂的控制释放复合物组合物，以设计成通过施用具有不同起始时间的成分来控制以特定速率释放的每种成分，并且对于 治疗高血压并预防具有糖尿病，肥胖症，高脂血症，冠状动脉疾病等的代谢综合征的患者的并发症。 控制释放复合物组合物包含延迟时间延迟释放部分，其包括作为活性成分的血管紧张素-II受体阻断剂和包含HMG-CoA还原酶抑制剂作为活性成分的速释部分，其中所述血管紧张素-II受体阻断剂 选自氯沙坦，缬沙坦，厄贝沙坦，坎地沙坦，替米沙坦，依普罗沙坦，奥美沙坦及其药学上可接受的盐，HMG-CoA还原酶抑制剂是选自辛伐他汀，洛伐他汀，阿托伐他汀，匹伐他汀 瑞舒伐他汀，氟伐他汀，普伐他汀及其药学上可接受的盐，延迟时间延迟释放部分包括选自肠溶性聚合物，水不溶性聚合物，疏水性化合物和亲水性聚合物的释放控制材料。 此外，组合物中含有5〜1200mg的血管紧张素-II受体阻断剂。
-
79.发明公开
公开(公告)号：KR1020080039302A
公开(公告)日：2008-05-07
申请号：KR1020070109641
申请日：2007-10-30
Applicant: 한올바이오파마주식회사
IPC: A61K9/22 , A61K31/495
CPC classification number: A61K31/00 , A61K9/2086 , A61K9/209 , A61K31/549 , A61K45/06 , A61K2300/00
Abstract: A pharmaceutical composition comprising a thiazide compound and an angiotensin-II-receptor blocker is provided to maximize the pharmacological and clinical antihypertensive effects and complication preventive effects of drugs and reduce the side effects of the drugs. A controlled release oral pharmaceutical composition comprises a thiazide compound or a pharmaceutically acceptable salt thereof and an angiotensin-II-receptor blocker or a pharmaceutically acceptable salt thereof as active ingredient, wherein after the oral administration of the composition, the thiazide compound or pharmaceutically acceptable salt thereof is immediately released, and angiotensin-II-receptor blocker or pharmaceutically acceptable salt thereof is released in an intended lag time delayed manner. A method for preparing the composition comprises the steps of: (a) mixing or granulating an angiotensin-II-receptor blocker with pharmaceutically acceptable additives to obtain a mixture or granules, optionally compressing the granules or mixture into a tablet using a tabletting machine and coating the tablet with a coating solution to obtain a delayed-release tablet; (b) obtaining particles or granules from a mixture of a thiazide compound with pharmaceutically acceptable additives to obtain a mixture, optionally dissolving or suspending the particles or granules with a film coating agent to obtain a coating solution, thereby obtaining an immediate release formulation; and (c) mixing the particles, granules or coating solution, obtained from the steps(a) and (b), with pharmaceutically acceptable excipients, and tabletting, coating or filling the mixture, thereby obtaining a desired composition. Further, the 5 to 100 mg of thiazide compound is comprised in the composition.
Abstract translation: 提供包含噻嗪类化合物和血管紧张素-II-受体阻断剂的药物组合物以最大化药物的药理学和临床抗高血压作用和并发症预防作用，并减少药物的副作用。 控释口服药物组合物包含噻嗪类化合物或其药学上可接受的盐和血管紧张素-II-受体阻断剂或其药学上可接受的盐作为活性成分，其中在口服给药组合物后，将噻嗪类化合物或其药学上可接受的盐 立即释放血管紧张素-II受体阻断剂或其药学上可接受的盐，以期望的延迟时间方式释放。 制备组合物的方法包括以下步骤：（a）将血管紧张素-II受体阻断剂与药学上可接受的添加剂混合或制粒以获得混合物或颗粒，任选地使用压片机和涂层将颗粒或混合物压片成片剂 该片剂具有涂层溶液以获得缓释片剂; （b）从噻嗪类化合物与药学上可接受的添加剂的混合物中获得颗粒或颗粒以获得混合物，任选地用薄膜包衣剂将颗粒或颗粒溶解或悬浮以获得涂布溶液，从而获得即时释放制剂; 和（c）将由步骤（a）和（b）获得的颗粒，颗粒或涂布溶液与药学上可接受的赋形剂混合，并压制，涂覆或填充混合物，从而获得所需的组合物。 此外，组合物中包含5至100mg的噻嗪类化合物。
-
公开(公告)号：KR1020080018841A
公开(公告)日：2008-02-28
申请号：KR1020070085480
申请日：2007-08-24
Applicant: 한올바이오파마주식회사
IPC: A61K9/22
CPC classification number: A61K45/06 , A61K9/1635 , A61K9/1652 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/4808 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5084 , A61K31/20 , A61K31/40 , A61K31/4422 , A61K2300/00
Abstract: A controlled release complex formulation comprising dihydropyridine calcium channel blockers and HMG(3-hydroxy-3-methylglutaryl)-CoA reductase inhibitors is provided to improve anti-hypertension effects in a synergism manner by releasing the drugs in a different time and inhibiting side effects caused by reacting them. A controlled release complex formulation comprises 1-20 mg of dihydropyridine calcium channel blockers in a controlled release partition and 5-160 mg of statin lipid lowering agents such as HMG-CoA reductase inhibitors in a rapid release partition, wherein the dihydropyridine calcium channel blockers and statin lipid lowering agents are related to an identical cytochrome P 450 enzyme and show antagonistic function when they are present in the liver simultaneously.
Abstract translation: 提供包含二氢吡啶类钙通道阻断剂和HMG（3-羟基-3-甲基戊二酰基）-CoA还原酶抑制剂的控制释放复合物制剂，以通过在不同时间内释放药物并抑制引起的副作用以协同方式改善抗高血压作用 通过他们的反应。 控制释放复合物制剂包含1-20mg在控制释放分配物中的二氢吡啶类钙通道阻断剂和5-160mg的快速释放分配中的5-60mg他汀类降脂药如HMG-CoA还原酶抑制剂，其中二氢吡啶钙通道阻断剂和 他汀类降脂药与相同的细胞色素P 450酶相关，并且当它们同时存在于肝脏中时显示出拮抗作用。
-
-
-
-
-
-
-
-
-
Search Results
108
records
(took 0.039 seconds)
